Metamizol Teva

Metamizole Sodium Monohydrate, the active ingredient in Metamizol Teva, is an analgesic, antipyretic presented as an oral formulation for oral use. It is employed to relieve moderate to severe pain and to reduce fever in adult patients. GNH USA supplies Metamizol Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol acts as a potent analgesic and antipyretic across several clinical situations. - Pain: provides effective relief of moderate to severe acute pain. - Fever: lowers elevated body temperature in febrile states. - Postoperative pain: helps control pain following surgical procedures.

Metamizole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: occasional upset stomach and vomiting. - Dizziness: transient light‑headedness or vertigo. - Headache: mild to moderate head pain. - Rash: skin redness or itching. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Anaphylaxis: rapid, severe allergic response requiring emergency care. - Hepatotoxicity: abnormal liver enzyme elevations. - Renal impairment: decreased kidney function in susceptible individuals.

Before prescribing Metamizol, clinicians should consider several safety measures. - Renal function assessment: evaluate kidney status, especially in elderly patients. - Hematologic monitoring: perform regular blood counts to detect early signs of agranulocytosis. - Hepatic caution: use carefully in patients with liver disease. - Hypersensitivity screening: avoid in individuals with known allergy to metamizole or related compounds. - Concomitant NSAIDs: limit use with other non‑steroidal anti‑inflammatory drugs to reduce additive toxicity. - Store at room temperature: keep in the original pack, protect from moisture.

Metamizol can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other myelotoxic agents: combined use may increase risk of severe blood dyscrasias. - Concurrent NSAIDs: heightened potential for gastrointestinal bleeding and renal injury. - Anticoagulants: may amplify anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely): - Diuretics: concurrent therapy may affect renal clearance of Metamizol. - Alcohol: excessive intake can increase gastrointestinal irritation and dizziness.